A Phase IV, Multicenter, Randomized, Single-blinded (Evaluator), Active-controlled, Parallel Study for Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Moderate to Severe Dry Eye Disease Patients

Conditions:   Dry Eye;   Dry Eye Syndromes Interventions:   Drug: TJO-018;   Drug: Cyclosporine Ophthalmic Emulsion 0.05%;   Drug: TJO-018 + Cyclosporine Ophthalmic Emulsion 0.05% Sponsor:   Taejoon Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials